News | News By Subject | News by Disease News By Date | Search News

Blood Disorders (misc) News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Seattle's Omeros (OMER) Fires Back But Still Won't Answer Basic Questions About Key Drug     8/24/2017
Bay Area's Portola (PTLA) Rockets as the FDA Approves First and Only Anticoagulant for Hospitals     6/27/2017
bluebird bio (BLUE) Touts Impressive Data From Late-Stage Gene Therapy Study     6/26/2017
Questions Arise Over the World's Richest Doctor's 'Breakthrough' Cancer Therapy Promo Videos     3/28/2017
FDA Deals Another Blow to AstraZeneca PLC (AZN)'s Blood Drug     3/20/2017
The Franchise That Could Bring in Another $20 Billion for Celgene (CELG)     11/23/2016
Investors Elated as Relypsa (RLYP)'s Phase IV Study of Veltassa Successful     8/31/2016
Bay Area's Portola (PTLA) Plummets as FDA Rejects AndexXa NDA     8/19/2016
Bad News for AstraZeneca PLC (AZN) is Good News for Relypsa (RLYP)     5/31/2016
Bay Area's Relypsa (RLYP) Falls on Unimpressive Veltassa Script Data     5/17/2016
Alnylam (ALNY)’s John Maraganore Provides Leadership for RNAi Development and Biotech Industry     4/4/2016
Portola (PTLA) Craters as Long-Acting Blood Thinner Betrixaban Missed Primary Goal in Phase III Study     3/25/2016
Eagle Pharma (EGRX) Plunges as the FDA Rejects Blood Thinner Kangio     3/18/2016
AstraZeneca PLC (AZN), Novo Nordisk A/S (NVO) Investors Pin Hopes on Data from Two Closely-Watched Trials     3/2/2016
Why Investors are Waiting Anxiously for Alnylam (ALNY)'s Blood Disease Data     12/4/2015

News from Around the Web
FDA Confirms Becton, Dickinson and Company (BDX) Blood Tubes Not Linked to Inaccurate Lead Results     8/18/2017
Uproar Ensues as Pfizer (PFE) Sends 58 Israeli Doctors to Conference Promoting Its Blood-Thinning Drug Eliquis     3/29/2017
Why Ionis Pharma (IONS)'s Extensive And Deep Pipeline Could Get Investors' Hearts Pumping     3/8/2017
How Bristol-Myers Squibb (BMY) And Pfizer (PFE) Are Stomping On Their Blood Thinner Rivals     2/17/2017
Experimental Tools To Clean Infected Blood Raise Hope For Fighting Major Killer, Harvard Medical School Study     3/23/2016
Novel Device Measures Stiffness And Stickiness Of Red Blood Cells, Case Western Reserve University Study     3/2/2016
Electric Fields Remove Nanoparticles From Blood With Ease, University of California, San Diego (UCSD) Study     11/24/2015
What Is Artificial Blood And Why Is The UK Going To Trial It?     6/25/2015
Extreme Exercise Linked To Blood Poisoning, Monash University Study     6/18/2015
How A Fluke Led Acceleron Pharma To A Crippling Blood Disease     7/18/2014
New Therapy for Blood Cancers Using Drug Combo, Report in Clinical Cancer Research     6/3/2011
Acetaminophen Tied to Blood Cancers, Fred Hutchinson Cancer Research Center Study     5/10/2011
IVIg No Help in Neonatal Blood Disease, Leiden University Medical Center Study Finds     3/21/2011
Higher Levels of Blood Protein Linked to Lower Respiratory Risks, University College London Study     2/16/2011
Breast Implants Linked to Blood Cancer, FDA Says     1/27/2011

Press Releases
Argenx Reaches 50% Enrollment In Phase II Clinical Trial Of ARGX-113 In Immune Thrombocytopenia     9/20/2017
Data On Delcath Systems (DCTH)’s CHEMOSAT System Presented At CIRSE Annual Meeting     9/19/2017
Masimo (MASI) Release: Study Evaluates Utility Of Masimo SpHb During High-Blood-Loss Oncosurgery     8/28/2017
ClearFlow Announces Positive U.S. Clinical Trial Results     8/21/2017
Relypsa (RLYP) Announces European Approval Of Veltassa To Treat Adult Patients With Hyperkalemia (Elevated Blood Potassium Levels)     7/21/2017
Novartis AG (NVS) Makes Another Dent Into The Biosimilar Market With Approval Of Rixathon     6/19/2017
Edge Therapeutics Receives Pediatric Investigation Plan Waiver From The EMA     6/8/2017
Vifor Pharma Release: CHMP Recommends Veltassa For The Treatment Of Hyperkalaemia In The EU     5/19/2017
Editas Medicine (EDIT) Announces Pre-Clinical Data For Program To Treat Sickle Cell Disease And Beta-Thalassemia     5/11/2017
Akari Therapeutics Demonstrates Positive Response With Coversin In Ongoing Phase II PNH Trial And In Additional Clinical Targets     4/24/2017
Sandoz Proposed Biosimilars Rituximab And Etanercept Recommended For Approval In Europe*     4/24/2017
Relypsa (RLYP) Presents Veltassa Phase IV Data Showing Consistent Efficacy And Safety Whether Taken With Or Without Food In Patients With Hyperkalemia     4/20/2017
Achillion (ACHN) Announces Initiation Of Patient Dosing In Phase II Study Of ACH-4471 For Paroxysmal Nocturnal Hemoglobinuria     4/6/2017
Akari Therapeutics Announces FDA Fast Track Designation For Coversin     3/31/2017
After Much Anticipation, Cellectar Biosciences  (CLRB) Initiates NCI-Supported Phase II Trial Of CLR 131 In Multiple Myeloma And Other Blood Cancers     3/30/2017

//-->